Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

..... MDSC's....MDSC's....MDSC's.... its becoming apparent that Dmitry Gabrilovich went with Peregrine Pharmaceuticals because they have Bavituximab (PS Targeting) which reduces MDSC's in a significant way and what happens after is astronomical, in that it helps create an optimal immune response.

Ask yourself why Dmitry went with Peregrine?

Ask yourself why all the sabotage attempts?

I believe I know the answer of so many questions and if a simple landscaper can figure it out.... so can you.

Now.... more being reported from the corner of Dmitry...

--------------------------------------------------------

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

Thomas Condamine1,*,
George A. Dominguez1,
Je-In Youn1,†,
Andrew V. Kossenkov1,
Sridevi Mony1,
Kevin Alicea-Torres1,
Evgenii Tcyganov1,
Ayumi Hashimoto1,
Yulia Nefedova1,
Cindy Lin1,
Simona Partlova1,‡,
Alfred Garfall2,3,
Dan T. Vogl2,3,
Xiaowei Xu2,
Stella C. Knight4,
George Malietzis4,5,
Gui Han Lee4,5,
Evgeniy Eruslanov2,
Steven M. Albelda2,3,
Xianwei Wang6,
Jawahar L. Mehta6,
Meenakshi Bewtra3,
Anil Rustgi2,3,
Neil Hockstein7,
Robert Witt7,
Gregory Masters7,
Brian Nam7,
Denis Smirnov8,
Manuel A. Sepulveda8 and
Dmitry I. Gabrilovich1,§

- Author Affiliations


1 Wistar Institute, Philadelphia, PA 19104, USA.

2 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

3 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

4 Antigen Presentation Research Group, Imperial College London, London HA1 3UJ, UK.

5 St. Mark’s Hospital, Harrow HA1 3UJ, UK.

6 Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

7 Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA.

8Janssen Oncology Therapeutic Area, Janssen Research and Development LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19477, USA.

?§Corresponding author. Email: [e-mail]

?* Present address: Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.

?† Present address: Wide River Institute of Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, South Korea.

?‡ Present address: SOTIO a.s., Prague, Czech Republic.

Science Immunology 05 Aug 2016:
Vol. 1, Issue 2, pp. aaf8943
DOI: 10.1126/sciimmunol.aaf8943

http://immunology.sciencemag.org/content/1/2/aaf8943



-------------------------------------------------------

Science sub Journal: Cancer direct accomplices "magic mirror"

Source: WuXi PharmaTech / Author: / 2016-08-30

For cancer patients, myeloid-derived immune regulation function of inhibiting the presence of cells (MDSC) is a vexing problem. Such cells are neutrophils and inhibit the immune system attack, and therefore is an important factor for cancer chemotherapy, targeted therapy and immune therapy resistant, and multi-core myeloid-derived suppressor cells ( PMN-MDSC) is one of the most important category. We could design a therapy for such cells to strengthen the immune system to attack tumors. However, since it has not been found separately from other regions neutrophil marker molecules may be, scientists are unable to carry out comprehensive and systematic study of MDSC.

Now, this issue has finally been resolved. Scientists from the United States Wistar Institute found capable of PMN-MDSC and other neutrophil molecular markers to distinguish LOX-1 protein, and thus they conducted in-depth research. Their results are published in "Science Immunology" published a recent Science child.

"Before this, people can not distinguish from a tumor in the PMN-MDSC out only by density gradient centrifugation to separate it," Professor of the article corresponding author Dmitry I. Gabrilovich said: "We found after such a molecular marker, people It will be able to be more in-depth study. in addition, if our clinical findings can be confirmed in larger studies, doctors and patients can be worked out in order to better treatment options, and even expected to help find new drug targets . "

Studies have shown that between PMN-MDSC and other neutrophils in the gene expression profiles there are significant differences in the PMN-MDSC endoplasmic reticulum stress-related gene expression was significantly higher. Among them, low-density lipoprotein (LDL) and its receptor, lectin-like oxidized low density lipoprotein receptor -1 (LOX-1) is the most high expression levels of protein, especially the latter. In extracted from healthy blood neutrophils hardly detected any trace of LOX-1, and extracted from the non-small cell lung cancer and head and neck cancer patients and blood neutrophils respectively are 5 cells and 15% 15-50% of the cell surface protein LOX-1. It is noteworthy that, LOX-1 positive neutrophils in patients with tumor volume ratio of the above-mentioned positive correlation.

In vitro, only the LOX-1 positive neutrophils exhibited the ability to suppress the immune response, while others had not it neutrophil characteristics. In addition, if taken from healthy neutrophils were endoplasmic reticulum stress-induced, the LOX-1 expression levels will rise, and one part of the cell becomes PMN-MDSC immune suppression function.

"Now we finally have MDSC molecular markers, and therefore can be the biological characteristics and clinical significance of such cells deeper exploration," Professor Dmitry I. Gabrilovich said.



References:

[1] Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

[2] Wistar scientists identify marker for myeloid-derived suppressor cells

https://translate.google.com/translate?hl=en&sl=zh-CN&u=www.bio360.net/news/show/29440&prev=search

--------------------

Unique pattern of PMN-MDSC migration in cancer

Sima Patel1, Thomas Condamine1, George Dominguez1, Simona Partlova1, Lucia R Languino2, Robert H Vonderheide3 and Dmitry Gabrilovich1

-
Author Affiliations

1Wistar Inst.
2Thomas Jefferson Univ.
3Univ. of Pennsylvania

Abstract

Myeloid-derived suppressor cells (MDSC) are pathologically activated immature myeloid cells that contribute to an immunosuppressive tumor microenvironment. In order to exert their effects at either the primary tumor site or in metastases, PMN-like MDSC (PMN-MDSC) must first migrate to these sites. There is some evidence to suggest that chemokine gradients can mediate their recruitment. We have observed that human PMN-MDSC accumulation in colon and lung tumors strongly correlates with the expression of S100A9, CXCL1 and CXCL8 in those tumors. Moreover, we have found that, in comparison to PMN, patient PMN-MDSC have an increased chemotactic response to CXCL8 in spite of decreased cell surface CXCR2 expression. Similarly, in murine transgenic models of melanoma, pancreatic and prostate cancer, we have found that PMN-MDSC migrate more than PMN when stimulated with CXCL1, in spite of similar levels of cell surface CXCR2 expression. Interestingly, murine PMN-MDSC are more migratory even without stimulation, and have greater speed, mean squared displacement and random motility coefficient than PMN. It is possible that in addition to specific factors secreted in the primary and metastatic tumor sites, PMN-MDSC recruitment to these sites is regulated by an altered migratory behavior of the cells themselves.

http://www.jimmunol.org/content/196/1_Supplement/119.8